American Society of Clinical Oncology Titles

American Society of Clinical Oncology

1. American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants. This updates a previously published guideline summary.

GUIDELINE TITLE
American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants.

BIBLIOGRAPHIC SOURCE(S)
Hensley ML, Hagerty KL, Kewalramani T, Green DM, Meropol NJ, Wasserman TH, Cohen GI, Emami B, Gradishar WJ, Mitchell RB, Thigpen JT, Trotti A 3rd, von Hoff D, Schuchter LM. American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants. J Clin Oncol 2009 Jan 1;27(1):127-45. [50 references] PubMed

GUIDELINE STATUS
This is the most current release of the guideline.

This guideline updates a previously released version: Schuchter LM, Hensley ML, Meropol NJ, Winer EP. 2002 update of recommendations for the use of chemotherapy and radiotherapy protectants: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2002 Jun 15;20(12):2895-903. [28 references] PubMed

open here to see the full-text:
http://www.guideline.gov/summary/summary.aspx?ss=15&doc_id=15228&nbr=&string=


2. American Society of Clinical Oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. This updates a previously published guideline summary.

GUIDELINE TITLE
American Society of Clinical Oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction.

BIBLIOGRAPHIC SOURCE(S)
Visvanathan K, Chlebowski RT, Hurley P, Col NF, Ropka M, Collyar D, Morrow M, Runowicz C, Pritchard KI, Hagerty K, Arun B, Garber J, Vogel VG, Wade JL, Brown P, Cuzick J, Kramer BS, Lippman SM, American Society of Clinical Oncology. American Society of Clinical Oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. J Clin Oncol 2009 Jul 1;27(19):3235-58. [127 references] PubMed

GUIDELINE STATUS
This is the current release of the guideline.

This guideline updates a previous version: Chlebowski RT, Col N, Winer EP, Collyar DE, Cummings SR, Vogel VG 3rd, Burstein HJ, Eisen A, Lipkus I, Pfister DG. American Society of Clinical Oncology technology assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, raloxifene, and aromatase inhibition. J Clin Oncol 2002 Aug 1;20(15):3328-43. [119 references] PubMed

open here to see the full-text:
http://www.guideline.gov/summary/summary.aspx?ss=15&doc_id=15229&nbr=&string=


3. Use of 5-alpha-reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology-American Urological Association 2008 Clinical Practice Guideline.

GUIDELINE TITLE
Use of 5-alpha-reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology-American Urological Association 2008 Clinical Practice Guideline.

BIBLIOGRAPHIC SOURCE(S)
Kramer BS, Hagerty KL, Justman S, Somerfield MR, Albertsen PC, Blot WJ, Ballentine Carter H, Costantino JP, Epstein JI, Godley PA, Harris RP, Wilt TJ, Wittes J, Zon R, Schellhammer P, American Society of Clinical Oncology Health Services Committee, American Urological Association Practice Guidelines Committee. Use of 5-alpha-reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline. J Clin Oncol 2009 Mar 20;27(9):1502-16. [51 references] PubMed

GUIDELINE STATUS
This is the current release of the guideline.

open here to see the full-text:
http://www.guideline.gov/summary/summary.aspx?ss=15&doc_id=15227&nbr=&string=